Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests

Drug treatments from Bristol-Myers Squibb (BMY) and Merck (MRK) designed to battle lung cancer both topped expectations in lung cancer, the companies said Monday, but Bristol shares plunged after Merck`s combination proved to be stronger.

Both firms tested drugs that harness a patient`s immune system to fight cancer. A regimen of Bristol`s Opdivo and Yervoy, two immuno-oncology drugs, cut the risk of cancer progression or death by 42% compared with chemotherapy.

Merck`s regimen, however, used a combination of Keytruda and chemotherapy. That reduced the risk of death by 51%.

In early trading on the stock market today, Bristol tanked 5.2%, near 55.60. Merck, on the other hand, lifted 3.2%, near 59.

(c) 2018 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Source : http://www.4-traders.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Topples-After-Merck-Treatment-Outperforms-It-In-Lung-Cancer-Tests-26369303/

165
Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests

Source:4-Traders

Bristol Topples After Merck Treatment Outperforms It In Lung Cancer Tests